A Korean company specialised in in-vitro diagnostics is looking for partners, interested in developing and licensing, commercialising aptamer immuno-PCR technology for in-vitro diagnostics of prostate cancer.
A Korean company specialised in in-vitro diagnostics is looking for partners, interested in developing and commercialising aptamer immuno-PCR technology. This technology can detect not only prostate cancer but other types of cancers with 1000 times more sensitivity than the existing test technology, ELISA (Enzyme-Linked Immunosorbent Assay). The company prefers partners specialised in cancer diagnostics and in-vitro diagnostic kits under commercial, license, or research cooperation agreement.